logo

Trovagene Inc. (TROV)



Trade TROV now with
  Date
  Headline
9/30/2019 8:26:20 AM Trovagene Presents Results From Phase 1b/2 Study Of Onvansertib In Patients With Relapsed/refractory AML
9/19/2019 8:16:36 AM Trovagene Reports Completion Of Phase 1b Trial Of Onvansertib In Acute Myeloid Leukemia
8/26/2019 8:08:31 AM Trovagene Presents Positive Clinical Data From Ongoing Phase 2 Study Of Onvansertib In MCRPC
7/9/2019 8:05:16 AM Trovagene Announces Initiation Of Enrollment For Phase 1b/2 Clinical Trial In KRAS-Mutated Colorectal Cancer
5/23/2019 8:13:39 AM Trovagene And Nektar Enter Research Collaboration To Explore Combination Of Onvansertib And ONZEALD
5/7/2019 4:21:59 PM Trovagene Q1 Loss/share $1.02 Vs. Loss $6.23 Year Ago
4/23/2019 8:09:16 AM Trovagene Announces Data Demonstrating Significant Synergy Of Onvansertib In Combination With Venetoclax
4/5/2019 8:19:25 AM Trovagene Announces Update To Phase 1b/2 AML Trial Data Presented
4/2/2019 8:06:21 AM Trovagene Presents Early Data From Ongoing Phase 2 Study Evaluating Onvansertib In Combination With Zytiga
3/13/2019 8:31:17 AM Trovagene Receives $3.0 Mln From Exercise Of Warrants
3/12/2019 8:32:36 AM Trovagene Regains Compliance With Nasdaq Listing Requirements
3/6/2019 4:29:32 PM Trovagene Q4 Loss/share $1.09 Vs. Loss $4.61 Year Ago
  
 
>